

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT
APPLICATION ACCEPTED FOR CLINICAL TRIAL OF
HUMAN RABIES mRNA VACCINE AGAINST RABIES VIRUS

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that on June 10, 2023, the clinical trial application for the Group’s human rabies mRNA vaccine against the rabies virus was accepted by the PRC National Medical Products Administration, making it the first rabies mRNA vaccine to be submitted for clinical trial in the PRC.

Rabies mRNA vaccines have the following advantages over conventional human rabies vaccines: they provide better immunogenicity, and consequently fewer doses (two or three) are required to induce better immunity compared to traditional rabies vaccines (four or five doses); they are easier to produce, as production does not involve the complex processes of cell cultivation; they are easier to purify, as raw materials contain fewer impurities; greater consistency of the product from batch to batch; and they are expected to have a better safety profile given the absence of risks associated with injecting inactivated viruses or foreign cells into the human body.

Meanwhile, investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, June 12, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.